Amicus Therapeutics Inc

Amicus Therapeutics — Q3 2019 Earnings Presentation

23 slides from Amicus Therapeutics's earnings presentation, Nov 14, 2019

  1. Slide 1: 3Q19 Financial Results Conference Call & Webcast

    3Q19 Financial Results Conference Call & Webcast November 11, 2019

  2. Slide 2: Forward-Looking Statements

    Introduction 2 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinica

  3. Slide 3: A Leading Fully-Integrated, Global Rare Disease Biotechnology Company

    Introduction 3 A Leading Fully-Integrated, Global Rare Disease Biotechnology Company Gene Therapy World Class PLATFORM BIOLOGICS Protein Engineering Capabilities & Glycobiology AT-GAA Global Footprint Phase 3 in Robust R&D in 27 Countries Pompe Disease Engine Nearly 50+ Lysosomal GLOBAL Disorders an

  4. Slide 4: Key Takeaways for 3Q19 Results

    Introduction 4 Key Takeaways for 3Q19 Results Today’s Conference Call and Recent Analyst Day Highlight our Success and Outlook Across our Science, Clinical, Regulatory and Commercial Efforts Galafold Continues Amicus Financial AT-GAA for Pompe Portfolio of Gene Strong Launch Outlook Strengthened Adv

  5. Slide 5: Financial Summary

    Financial Summary “We have a duty to obsolete our own technologies” - Amicus Belief Statement

  6. Slide 6: 3Q19 Select Financial Results

    Financial Summary 6 3Q19 Select Financial Results 3Q19 Revenue of $48.8M Primarily from Global Galafold Sales Sept. 30, 2019 (in thousands, except per share data) Sept. 30, 2018 Product Revenue 48,768 20,596 Cost of Goods Sold 5,596 4,310 R&D Expense1 58,892 138,227 SG&A Expense 39,680 31,867 Change

  7. Slide 7: Cash Runway Now Well into 1H2022

    Financial Summary 7 Cash Runway Now Well into 1H2022 (2.5+ years) Fully Funded Through Major Milestones in Portfolio and Continued Global Growth $420M+ Well into Cash 2.5+ Years Cash Runway 1H2022 YE2019

  8. Slide 8: Financial Summary & Guidance

    Financial Summary 8 Financial Summary & Guidance Strong Balance Sheet with $514M+ Cash at 9/30/19 – Cash Runway Well into 1H2022 FINANCIAL POSITION Cash $514M Cash Runway1 Well Into 1H2022 Debt2 $152.8M CAPITALIZATION Shares Outstanding 254,772,163 FINANCIAL GUIDANCE FY19 Galafold Revenue Guidance $

  9. Slide 9: Financial Outlook: Key Takeaways

    Financial Summary 9 Financial Outlook: Key Takeaways • Company now fully funded through major milestones in portfolio and continued global growth • Cumulative Galafold projected revenues of $1B+ in 2020-2022 offset significant majority of company spend/investments • Achieved through OpEx savings, Ca

  10. Slide 10: Galafold Global Launch

    Galafold® (migalastat) Global Launch… …taking a leadership role in the treatment of Fabry disease “We push ideas as far and as fast as possible” - Amicus Belief Statement

  11. Slide 11: Galafold: Precision Medicine for Fabry Disease

    Galafold: Precision Medicine for Fabry Disease 11 Galafold Snapshot (as of September 30, 2019) Galafold is the Cornerstone of Amicus’ Success. It is an Orally Delivered Small Molecule Precision Medicine with a Unique Mechanism of Action for Fabry Patients with Amenable Variants that Replaces the Nee

  12. Slide 12: Galafold Global Launch Momentum

    Galafold: Precision Medicine for Fabry Disease 12 Galafold Global Launch Momentum (as of September 30, 2019) Global Commercial Metrics Continue to be Very Strong with >90% Compliance and Adherence, 30% Global Market Share of Treated Amenable Patients and Continued Broad Market Access 3Q19 Strength C

  13. Slide 13: Galafold Success and FY19 Revenue Guidance

    Galafold: Precision Medicine for Fabry Disease 13 Galafold Success and FY19 Galafold Revenue Guidance Strong Q3 Performance of $48.8M Gives Confidence in Upwardly Revised Guidance of $170M- $180M. We Expect to Fall in the Midpoint of this Revised Guidance, Inclusive of FX $170M - $180M $48.8M $44.1M

  14. Slide 14: Galafold Growth Trajectory

    Galafold: Precision Medicine for Fabry Disease 14 Galafold Growth Trajectory Galafold is on Track to Generate $1B+ in Projected Cumulative Revenues from 2020-2022 and is on an Anticipated Path to $500M+ in Annual Sales in 2023 and $1B+ Annual Sales at Peak $1B $500M+ Annual Revenue $1B Projected Cum

  15. Slide 15: Program Updates

    Program Updates “We have a duty to obsolete our own technologies” - Amicus Belief Statement

  16. Slide 16: AT-GAA: Updates & Key Takeaways

    AT-GAA for Pompe Disease 16 AT-GAA: Updates & Key Takeaways • PROPEL pivotal study expected to over-enroll (~120 Patients) by YE2019 • Pediatric study underway • Amicus natural history data (POM-002) generally AT-GAA for Pompe consistent with declines in 6MWT in published Advances Toward literature

  17. Slide 17: Gene Therapy: Updates & Key Takeaways

    Gene Therapy Portfolio 17 Gene Therapy: Updates & Key Takeaways • CLN6 Phase 2 interim data shows profound impact with potential to become first ever approved gene therapy for fatal brain disease in children • Additional patients to be dosed in Phase 2 study of CLN3 (largest cause of childhood neuro

  18. Slide 18: Closing Remarks

    Closing Remarks “We are business led and science driven” - Amicus Belief Statement

  19. Slide 19: 2019 Key Strategic Priorities

    Closing Remarks 19 2019 Key Strategic Priorities 1 Nearly double annual revenue for Galafold® (guidance $170M-$180M) Complete enrollment in AT-GAA Pivotal Study (PROPEL) and 2 report additional Phase 1/2 data Report additional 2-year clinical results in CLN6-Batten disease and 3 complete enrollment

  20. Slide 20: Our Passion for Making a Difference Unites Us

    Closing Remarks 20 Our Passion for Making a Difference Unites Us Amicus is Now at a Major Inflection Point and Positioned to Create Significant Shareholder Value Ahead while Advancing our Mission for Patients

  21. Slide 21: Thank You

    Thank You “Our passion for making a difference unites us” -Amicus Belief Statement

  22. Slide 22: Appendix

    Appendix

  23. Slide 23: Reconciliation

    Appendix Reconciliation Amicus Therapeutics, Inc. (in thousands) Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Total operating expenses - as reported $ 100,477 $ 172,467 $ 326,940 $ 307,835 GAAP Research and development: Share-based compensation 3,106 2,905 12,

Amicus Therapeutics — Q3 2019 Earnings Presentation on 6ix